INTRODUCTION
Monoclonal antibodies produced by hybrid cell lines have potential use in the therapy of human infection (1), malignancy (2) , and transplantation rejection (3) . However, human rather than murine monoclonal antibodies will be required to avoid sensitization to foreign proteins with their in vivo application (4) . As yet, protective human monoclonal antibodies have not been described and the optimal method for the production of human hybridoma antibodies is yet to be determined. Only limited success has been reported using human myeloma cell lines as fusion partners to immortalize antibody-producing lymphocytes (5, 6) . The rapid loss of human chromosomes from mouse myeloma-human lymphocyte hybrid cell lines has hampered the production of human antibody by this technique, although a few interspecies hybrids have been reported (7) (8) (9) . One possible way to circumvent the instability of interspecies hybrids would be to increase the number of hybrids initially secreting an antibody of predefined specificity, so that more attempts could be This report describes production of a stable hybrid cell line that secretes a human IgG antibody by fusing postimmunization human peripheral blood lymphocytes with the nonsecretor mouse myeloma line P3-X63-Ag 8.653 (10) . This monoclonal antibody (9F12) binds tetanus toxin in vitro and prevents tetanus in vivo in animals. The antigenic specificity of this antibody is described.
METHODS
Production of human monoclonal antibody. Peripheral blood mononuclear cells were obtained by Ficoll-Hypaque gradient centrifugation of heparinized peripheral blood collected from volunteers 6 or 7 d after immunization with tetanus and diphtheria toxoids adsorbed (for adult use) (Wyeth Laboratories, Marietta, PA). No volunteer had received a tetanus immunization within the preceding 2 yr and the individual from whom monoclonal antibody 9F12 was derived was last immunized -10 yr earlier. An enriched B lymphocyte fraction was prepared by incubating the mononuclear cells with 2-aminoethylisothiouronium bromide-treated sheep erythrocytes followed by Ficoll-Hypaque gradient centrifugation to remove lymphocytes rosetting with the erythrocytes (11) . The enriched B cells were fused with an equal number of P3-X63-Ag 8.653 mouse myeloma cells, according to a standard fusion protocol (12) , using 50% polyethylene glycol 6000 (Fisher Scientific Co., Fairlawn, NJ) as the fusing agent. After fusion, the cells were maintained in RPMI 1640 media containing 15% fetal calf serum, 2 X l0' M glutamine, 1 X 10-3 M sodium pyruvate, 100 U/ml penicillin, 100 ,ug/ml gentamicin, 1 X lo-4 hypoxanthine, 1.6 X 10' M thymidine (Gibco Laboratories, Grand Island Biological Co., Grand Island, NY), 4 X The hybrid supernatants were screened for antitetanus toxoid antibody production using an enzyme-linked immunosorbent assay (ELISA)' in microtiter plates (Microbiological Associates, Walkersville, MD) preincubated with 100 ,ul of purified tetanus toxoid (Massachusetts Public Health Biologic Laboratories, Boston, MA) at 10,ug/ml. Antibody binding to tetanus toxoid was identified with alkaline phosphatase-labeled antisera specific for human immunoglobulin (Ig)G, IgA, and 1gM (Atlantic Antibodies, Scarborough, ME) prepared and tested for specificity as has been previously described (13) . ELISA assays were also performed with diphtheria toxoid (NMassachusetts Public Health Biologic Laboratories), at 1 gig/ml.
Antibody-secreting hybrids were passed several times at d-10 cells/microtiter well that contained a mouse macrophage feeder layer. After five of these low density passages, hybrid 9F12 was cloned twice in a limiting dilution assay at 1 cell/well (14) .
Characterization of 9F12. The antibody from the tissue culture supernatant was concentrated -10-fold by precipitation with an equal volume of saturated ammonium sulfate (SAS) followed by dialysis against phosphate-buffered saline (PBS). Immunoglobulin heavy and light chain were determined bv Ouchterlony immunodiffusion using goat anti-human and anti-mouse antisera (N. L. Cappel Laboratories, Cochranville, PA). The concentration of antibody in tissue culture supernatant allowed to overgrow for several days was determined by radial immunodiffusion using an LC-partigen IgG kit (Calbiochem-Behring Corp., La Jolla, CA).
Determtinationt of the antigenic specificity of 9F12. Purified tetanus toxin was radioiodinated by the lactoperoxidase method using Enzymobeads (15) (Bio-Rad Laboratories, Richmond, CA). The iodinated toxin (1 pCi/btg) was incubated with papain (Boehringer Mannheim Biochemicals, Indianapolis, IN) at a ratio of 2 U papain/mg toxin for 3 h at 55°C as previously described (16) . SAS concentrated hybridoma supernatant and human serum were then incubated with the papain digest for 1.5 h at 40C and antigen-antibody complexes were precipitated with formalin-fixed Staphylococcus aureus, strain Cowan 1 (Enzyme Center, Inc., Boston, MA). The precipitate was washed three times with PBS and prepared for SDS-polyacrylamide gel electrophoresis by vortexing the pellet with SDS sample buffer, incubating for 5 min at 20°C, centrifuging the sample and then boiling the supernatant for 2 min before applying it to a 7.5% SDSpolyacrylamide gel. The gel was then fixed and autoradiography performed with Kodak X-Omat AR film.
Mouse toxin neutralization assay. The biologic activity of 9F12 was investigated using the mouse tetanus toxin neutralization assay (17) . Purified tetanus toxin (lot 39, Massachusetts Public Health Biologic Laboratories) in PBS with 0.2% gelatin (PBS-G) was diluted with an equal volume of either PBS-G, 10-fold SAS concentrated mouse myeloma cell tissue culture supernatant (653), or 10-fold SAS concentrated human monoclonal antibody 9F12 and administered as a 0.5-ml subcutaneous injection to the right inguinal fold of 15-18-g female CD-1 mice (Charles River Laboratories, Wilmiington, MA). The minimal lethal dose of this toxini preparation, defined as 100% death by 96 h, was 0.16 ng. ' Abbreviations used in this paper: ELISA, enzyme-linked immunosorbent assay; SAS, saturated ammonium sulfate.
RESULTS AND DISCUSSION
B lymphocytes prepared for fusion were harvested on days 6 or 7 postimmunization, which in preliminary studies corresponded to the time of peak in vitro antitetanus toxoid antibody production, confirming previously published data (18) . In the fusion from which clone 9F12 was derived, 6 X 106 B lymphocytes were initially seeded into 80 microtiter wells. Hybrids were observed in 28 of the 80 wells by 3 wk after fusion. 5 of the 28 wells contained human antitetanus toxoid antibody, all of the IgG isotype. Four of the five wells were passed at 10 cells/well and reassayed for continued antibody production. After several cycles of this procedure, one clone, 9F12, continued to produce high titers of antibody of the IgG class with k light chain (Fig. 1) Protective Human Hybridoma Antibody to Tetanus Toxin sity passage was attempted on three of the secreting hybrids but we were unable to maintain antibody production for >1 mo. Human antidiphtheria toxoid antibody was detected in supernatants of 3 of the 122 hybrids. No supernatants reacted with both tetanus and diphtheria toxoids.
We were able to demonstrate the protective capacity of this human hybridoma antibody using the mouse tetanus toxin neutralization assay. Data from a representative experiment are shown in Table I . All 15 animals that received tetanus toxin neutralized by preincubation with antibody 9F12 were completely protected. On the other hand, all 34 animals that received toxin preincubated with PBS-G, or the parent mouse myeloma cell culture supernatant, were either killed or paralyzed by the toxin. These results were reproducible in four replicate determinations. To the best of our knowledge, this is the first demonstration of toxin neutralization by a hybridoma antibody. The possibility does exist that there could be a mutant tetanus toxin which would not be neutralized by monoclonal antibody 9F12. However, mutant forms of tetanus toxin have never been described.
Tetanus toxin has a molecular weight of -150,000 and consists of two polypeptide chains linked by a disulfide bond. With reduction, the extracellular form of the toxin is split into its constituent heavy and light chains. Papain digestion cleaves the molecule into a 47,000-mol wt fragment C and an -95,000-mol wt fragment B (16) . Fragment C consists of the carboxy terminal half of the heavy chain and is responsible for the binding of the toxin to its in vivo receptor (19) . Fragment B consists of the remaining portion of the heavy chain linked to the entire light chain. Although the function of fragment B is unknown, it is hypothesized to contain the toxin principle of the molecule (20) .
Hybridoma antibody 9F12 binds both intact tetanus toxin and toxin fragment B (Fig. 2) . Serum The advent of monoclonal antibody technology has rekindled an interest in the passive immunotherapy of various human diseases. However, up to this point, most monoclonal antibodies have been of mouse origin and protective human monoclonal antibodies have not been reported. This report demonstrates that it is possible to produce monoclonal antibodies of human origin with a specifically desired biologic functioni using readily accessible human lymphocytes. Specific antibody secretion occurred in 11% (13/122) of the mousehumani hybrids using postimmunizatioin human lymphocytes, which is comparable to restults obtained with intraspecies fusions. Recently, other investigators have also been successful in producing mouse-human fuisions after in vivo immunization (9) . The protective capacity of 9F12 against tetanus demonstrates that a monoclonal antibody can neuitralize this toxin and supports the prospect that human monoclonal antibody will have a role in the prevention and treatmenit of human infection.
